

February 13, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir/ Madam,

Sub: Press Release - Acrotech Biopharma Inc., Announces FDA Approval of ADQUEY™ (difamilast 1%) Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis

We enclose a copy of the Press Release that is being issued by the Company in connection with the receipt of US FDA approval for ADQUEY™ (difamilast 1%) Ointment for the treatment of mild-to-moderate atopic dermatitis by Acrotech Biopharma Inc., a wholly owned stepdown subsidiary of the Company.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Encl: as above

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad-500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivi, Ameerpet, Hyderabad - 500 038, Telangana, India. Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Hyderabad, India, February 13, 2026

Acrotech Biopharma Inc. Announces FDA Approval of ADQUEY™ (difamilast 1%) Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis

East Windsor, NJ — February 13, 2026 — Acrotech Biopharma Inc., a bio-pharmaceutical company focused on developing and commercializing innovative propriety medications, in collaboration with Otsuka Pharmaceutical Co., Ltd., today announces that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ADQUEY™ (difamilast 1%) ointment, for the topical treatment of mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged 2 and older.

ADQUEY is a novel, non-steroidal, topical phosphodiesterase 4 (PDE4) inhibitor. This approval provides a new non-steroidal, topical treatment option for the millions of Americans living with atopic dermatitis. "The approval of ADQUEY represents a significant milestone in our commitment to advancing dermatology care," said Ashish Anvekar, President of Acrotech Biopharma Inc. "Patients and clinicians have long sought effective, long-term, non-steroidal treatments that can manage both the inflammation and pruritus associated with eczema. We intend to bring this valuable treatment option to the patients in the U.S. as soon as possible."

Clinical Trial Results

FDA approval was supported by multiple studies including pivotal Phase III controlled trials, which demonstrated that a significantly greater proportion of patients treated with ADQUEY achieved Investigator's Global Assessment (IGA) success compared to vehicle (placebo) after four weeks of treatment. The safety profile of ADQUEY AD was consistent across all three trials. The most common adverse reactions ($\geq 1\%$ and greater than vehicle) was nasopharyngitis. Less common ($< 1\%$) adverse reactions in subjects treated with ADQUEY included application site folliculitis, contact dermatitis, application site rash, and molluscum contagiosum.

About Atopic Dermatitis

Atopic dermatitis also called eczema is a common and chronic condition that causes itchy, dry, and inflamed skin. It usually begins in childhood but can start at any age. (Source: American Academy of Dermatology)

About ADQUEY (difamilast 1%)

ADQUEY is a novel non-steroidal phosphodiesterase 4 (PDE-4) inhibitor formulated as a topical ointment designed for twice-daily application for the treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. ADQUEY demonstrates inhibitory activities on all phosphodiesterase (PDE) 4 subtypes. Difamilast was discovered and developed by Otsuka Pharmaceutical and has been licensed to Acrotech in the United States since 2021.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihaar, Ameerpet, Hyderabad - 500 038, Telangana, India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Indication

ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.

Important Safety Information

The most common adverse reactions reported ($\geq 1\%$) for ADQUEY ointment was nasopharyngitis (6%). Please see full Prescribing Information for ADQUEY.

About Acrotech Biopharma

Acrotech Biopharma Inc ("Acrotech") a step-down subsidiary of Aurobindo Pharma Ltd, India was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them. To learn more about Acrotech Biopharma, visit acrotechbiopharma.com

About Otsuka

Otsuka Pharmaceutical Co., Ltd. ("Otsuka") is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, please visit www.otsuka.co.jp

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 31 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over seven major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihaar, Ameerpet, Hyderabad - 500 038, Telangana, India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

To know more, please log on to www.aurobindo.com

For further information or queries, please contact:

Investor Relations | Corporate Communications
Phone: +91 40 66721211 / 66725000
Email: ir@aurobindo.com

Disclaimer:

This press release contains statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivilas, Ameerpet, Hyderabad - 500 038, Telangana, India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com